Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but O’Connor is hopeful that there are treatment regimens for this patient population that can work.
With expression of CD19 in MCL, there is some promise in the treatment landscape for CAR T-cells. Some early studies are showing promising observations for this, but researchers need to be aware of the risks and toxicities, O’Connor says. Since MCL tends to be a highly drug-resistant disease as well as incredibly aggressive, researchers need to focus on what patients they are enrolling and if they have a chance of benefiting from CAR T-cells.
Agents like acalabrutinib (Calquence), ibrutinib (Imbruvica), and phosphoinositide 3-kinase inhibitors may be able to help in controlling this disease prior to the addition of CAR T-cell therapies, but further research is necessary to confirm this. O’Connor believes this is an exciting field of research, but it will also be challenging.
For more resources and information regarding anticancer targeted therapies in mantle cell lymphoma: [ Ссылка ]
